Recruiting Major Depressive Disorder Studies in Little Rock
Study to Assess the Safety and Effectiveness of NMRA-335140-501
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who ...
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with placebo as an adjunctive therapy to an antidepressant i...
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD....
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder...
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants ...
Psilocybin for Major Depressive Disorder (MDD)
Approximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. P...
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depressive Disorder - Emerge...
About Major Depressive Disorder Clinical Trials in Little Rock
Major depressive disorder (MDD) is a severe form of depression characterized by persistent sadness, loss of interest, and impaired daily functioning. Treatment-resistant depression (TRD) affects patients who do not respond to standard therapies. Novel treatments like ketamine, psilocybin, and neuromodulation are being studied.
There are currently 7 major depressive disorder clinical trials recruiting participants in Little Rock, ARKANSAS. These studies are seeking a combined 3,682 participants. Research is being sponsored by Neumora Therapeutics, Inc., Janssen Research & Development, LLC, Neurocrine Biosciences and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Major Depressive Disorder Clinical Trials in Little Rock — FAQ
Are there major depressive disorder clinical trials in Little Rock?
Yes, there are 7 major depressive disorder clinical trials currently recruiting in Little Rock, ARKANSAS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Little Rock?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Little Rock research site will contact you about next steps.
Are clinical trials in Little Rock free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Little Rock studies also compensate for your time and travel.
What major depressive disorder treatments are being tested?
The 7 active trials in Little Rock are testing new therapies including novel drugs, biologics, and treatment approaches for major depressive disorder.
Data updated March 2, 2026 from ClinicalTrials.gov